Replimune Group, Inc. (REPL)
Automate Your Wheel Strategy on REPL
With Tiblio's Option Bot, you can configure your own wheel strategy including REPL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REPL
- Rev/Share 0.0161
- Book/Share 3.6793
- PB 1.641
- Debt/Equity 0.2267
- CurrentRatio 6.9399
- ROIC -0.7109
- MktCap 471285913.0
- FreeCF/Share -2.4898
- PFCF -2.0683
- PE -1.9719
- Debt/Assets 0.1626
- DivYield 0
- ROE -0.6934
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | REPL | Cantor Fitzgerald | Neutral | Overweight | -- | -- | July 30, 2025 |
| Downgrade | REPL | H.C. Wainwright | Buy | Neutral | -- | -- | July 23, 2025 |
| Downgrade | REPL | BMO Capital Markets | Outperform | Underperform | -- | $2 | July 23, 2025 |
| Downgrade | REPL | Barclays | Overweight | Equal Weight | -- | $3 | July 23, 2025 |
| Downgrade | REPL | Wedbush | Outperform | Neutral | -- | $4 | July 22, 2025 |
| Downgrade | REPL | JP Morgan | Overweight | Neutral | -- | $9 | July 22, 2025 |
| Downgrade | REPL | Leerink Partners | Outperform | Market Perform | -- | $3 | July 22, 2025 |
| Downgrade | REPL | Piper Sandler | Overweight | Neutral | -- | $3 | July 22, 2025 |
| Initiation | REPL | Cantor Fitzgerald | -- | Overweight | -- | -- | June 20, 2025 |
| Initiation | REPL | ROTH MKM | -- | Buy | -- | $17 | Aug. 28, 2024 |
News
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: July 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, July 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable …
Read More
Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm
Published: July 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC
Published: July 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, July 24, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company's stock …
Read More
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company's stock …
Read More
BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Block & Leviton LLP is investigating Replimune Group, Inc. (Nasdaq: REPL) for potential securities law violations. Investors who have lost money in their Replimune Group, Inc. investment should contact the firm to learn more about how they might recover those losses.
Read More
Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Replimune Group, Inc. (NASDAQ:REPL ) Q4 2025 Results Conference Call May 22, 2025 8:00 AM ET Company Participants Arleen Goldenberg - Senior Communications Leader Sushil Patel - Chief Executive Officer Chris Sarchi - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Anupam Rama - J.P. Morgan Roger Song - Jefferies Jonathan Chang - Leerink Allison Bratzel - Piper Sandler Peter Lawson - Barclays Operator Good morning and welcome to the Replimune Fiscal Year Fourth Quarter 2025 Financial Results and Corporate Update Conference Call.
Read More
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
• BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete • Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date • Conference call today at 8:00 AM ET WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2025 and provided a business update.
Read More
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025.
Read More
Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of …
Read More
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) plus nivolumab in advanced melanoma is enrolling Enrolled first patients in trials evaluating RP2 for the treatment of metastatic uveal melanoma and hepatocellular carcinoma WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2024 and …
Read More
About Replimune Group, Inc. (REPL)
- IPO Date 2018-07-20
- Website https://www.replimune.com
- Industry Biotechnology
- CEO Sushil Patel
- Employees 479